5/28
08:05 am
otlk
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
Low
Report
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
5/17
11:07 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
Low
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $30.00 price target on the stock.
5/15
05:16 pm
otlk
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update [Yahoo! Finance]
Low
Report
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update [Yahoo! Finance]
5/15
05:00 pm
otlk
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
Low
Report
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update
5/13
08:52 am
otlk
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD [Yahoo! Finance]
Low
Report
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD [Yahoo! Finance]
5/13
08:50 am
otlk
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
Low
Report
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMD
5/9
08:58 am
otlk
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast [Yahoo! Finance]
Medium
Report
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast [Yahoo! Finance]
5/9
08:45 am
otlk
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast
Medium
Report
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 2024 and Host Inaugural Quarterly Conference Call and Webcast
5/2
09:05 am
otlk
Outlook Therapeutics® to Present at the Retina World Congress 2024
Low
Report
Outlook Therapeutics® to Present at the Retina World Congress 2024
4/29
09:09 am
otlk
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase [Yahoo! Finance]
Medium
Report
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase [Yahoo! Finance]
4/29
09:00 am
otlk
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
Medium
Report
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase
4/15
04:15 pm
otlk
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
Medium
Report
Outlook Therapeutics® Announces Closing of Private Placement of $5.0 Million
3/31
09:29 am
otlk
Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval [Seeking Alpha]
High
Report
Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval [Seeking Alpha]
3/27
08:00 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $50.00 price target on the stock.
Low
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) was upgraded by analysts at BTIG Research from a "neutral" rating to a "buy" rating. They now have a $50.00 price target on the stock.
3/25
08:45 am
otlk
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target raised by analysts at HC Wainwright from $1.50 to $30.00. They now have a "buy" rating on the stock.
Low
Report
Outlook Therapeutics, Inc. (NASDAQ: OTLK) had its price target raised by analysts at HC Wainwright from $1.50 to $30.00. They now have a "buy" rating on the stock.
3/22
08:34 am
otlk
Outlook Therapeutics stock jumps on positive EU CHMP opinion for its wet AMD treatment [Seeking Alpha]
High
Report
Outlook Therapeutics stock jumps on positive EU CHMP opinion for its wet AMD treatment [Seeking Alpha]
3/22
07:44 am
otlk
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD [Yahoo! Finance]
Medium
Report
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD [Yahoo! Finance]
3/22
07:35 am
otlk
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
High
Report
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for Wet AMD
3/18
05:14 pm
otlk
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million [Yahoo! Finance]
Medium
Report
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million [Yahoo! Finance]
3/18
05:10 pm
otlk
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
Medium
Report
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
3/12
08:09 am
otlk
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split [Yahoo! Finance]
Medium
Report
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split [Yahoo! Finance]
3/12
08:05 am
otlk
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split
High
Report
Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split